This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhang, J. Articles by Mao, L. Search for Related Content PubMed PubMed Citation Articles by Zhang, J. Articles by Mao, L.

Down-regulation of Hepatoma-Derived Growth Factor Inhibits Anchorage-Independent Growth and Invasion of Non–Small Cell Lung Cancer Cells

Departments of ¹ Thoracic/Head and Neck Medical Oncology and ² Biostatisitcs, The University of Texas M.D. Anderson Cancer Center; ³ Cancer Biology Program, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas; and ⁴ Department of Thoracic Surgery, First Clinical College, China Medical University, Shenyang, PR China

Requests for reprints: Li Mao, Molecular Biology Laboratory, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Unit 432, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: 713-792-6363; Fax: 713-796-8655; E-mail: lmao{at}mdanderson.org.

We recently reported that a high level of hepatoma-derived growth factor (HDGF) expression in tumors correlates with a high incidence of tumor relapse or distant metastasis and shortened survival time in patients with non–small cell lung cancer (NSCLC). However, the mechanisms of the HDGF-associated aggressive biological behavior are unknown. In this study, we knocked down HDGF expression in NSCLC cells to determine the biological consequences. Transfection with HDGF-specific small interfering RNA (siRNA) resulted in down-regulation of HDGF expression in four NSCLC cell lines. Down-regulation of HDGF resulted in no detectable effect on anchorage-dependent cell growth as determined with a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, a microelectronic cell sensor system, and flow cytometry. In contrast, cells transfected with HDGF-siRNA grew more slowly and formed significantly fewer colonies in soft agar than did cells treated with LipofectAMINE alone or transfected with negative control siRNA. In an in vitro invasion assay, significantly fewer cells transfected with HDGF-siRNA than cells treated with LipofectAMINE alone were able to invade across a Matrigel membrane barrier. In an in vivo mouse model, A549 cells treated with HDGF-siRNA grown significantly slower than the cells treated with LipofectAMINE alone or negative control siRNA. Morphologically, HDGF-siRNA–treated tumors exhibited markedly reduced blood vessel formation and increased necrosis, whereas the Ki67 labeling indices were similar in tumors treated with controls. Our results suggest that HDGF is involved in anchorage-independent growth, cell invasion, and formation of neovasculature of NSCLC. These qualities may contribute to the HDGF-associated aggressive biological behavior of NSCLC. (Cancer Res 2006; 66(1): 18–23)

This article has been cited by other articles:

				H. Ren, Z. Chu, and L. Mao Antibodies targeting hepatoma-derived growth factor as a novel strategy in treating lung cancer Mol. Cancer Ther., May 1, 2009; 8(5): 1106 - 1112. [Abstract] [Full Text] [PDF]

				A. H. Stegh, H. Kim, R. M. Bachoo, K. L. Forloney, J. Zhang, H. Schulze, K. Park, G. J. Hannon, J. Yuan, D. N. Louis, et al. Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma Genes & Dev., January 1, 2007; 21(1): 98 - 111. [Abstract] [Full Text] [PDF]

				H. Uyama, Y. Tomita, H. Nakamura, S. Nakamori, B. Zhang, Y. Hoshida, H. Enomoto, Y. Okuda, M. Sakon, K. Aozasa, et al. Hepatoma-Derived Growth Factor Is a Novel Prognostic Factor for Patients with Pancreatic Cancer. Clin. Cancer Res., October 15, 2006; 12(20): 6043 - 6048. [Abstract] [Full Text] [PDF]